Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs

Biomaterials

Volumn 35, Issue 10, 2014, Pages 3340-3347

  Zhao, Jing ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biodegradable polymers; Cancer nanotechnology; Drug delivery; Drug targeting; Nanomedicine; Pharmaceutical nanotechnology

Indexed keywords

CANCER NANOTECHNOLOGY; DRUG-TARGETING; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2); NANOPARTICLE FORMULATION; NANOPRECIPITATION METHOD; SIZE AND SIZE DISTRIBUTIONS; TARGETED DELIVERY; THERAPEUTIC EFFECTS;

BIODEGRADABLE POLYMERS; CELLS; CHAIN LENGTH; CONJUGATED POLYMERS; CYTOTOXICITY; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; NANOTECHNOLOGY; SURFACE CHEMISTRY; THERMODYNAMICS;

NANOPARTICLES;

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MACROGOL; MACROGOL 1000; MACROGOL 2000; MACROGOL 3350; MACROGOL 5000; NANOPARTICLE; TOCOFERSOLAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR WEIGHT; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RESPONSE SURFACE METHOD; SURFACE CHARGE; SURFACE PROPERTY; THERMODYNAMICS; ZETA POTENTIAL;

BIODEGRADABLE POLYMERS; CANCER NANOTECHNOLOGY; DRUG DELIVERY; DRUG TARGETING; NANOMEDICINE; PHARMACEUTICAL NANOTECHNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYETHYLENE GLYCOLS; VITAMIN E;

EID: 84893641240     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.003     Document Type: Article

References (31)

1. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. Acs Nano 2009, 3:16-20.
2. Gu F.X., Karnik R., Wang A.Z., Alexis F., Levy-Nissenbaum E., Hong S., et al. Targeted nanoparticles for cancer therapy. Nano Today 2007, 2:14-21.
3. Zhang Z.P., Tan S.W., Feng S.S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33(19):4783-4974.
4. Zhang Z., Feng S.S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006, 27:4025-4033.
5. Zhang Z., Lee S.H., Gan C.W., Feng S.S. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008, 25:1925-1935.
6. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16:1550-1556.
7. Mi Y., Liu Y., Feng S.S. Formulation of docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
8. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
9. Sun B., Feng S.S. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) 2009, 4:431-445.
10. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
11. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
12. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280.
13. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23:5542-5551.
14. Amar S., Roy V., Perez E.A. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 2009, 114:413-422.
15. Bergstrom K., Holmberg K., Safranj A., Hoffman A.S., Edgell M.J., Kozlowski A., et al. Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces. J Biomed Mater Res 1992, 26:779-790.
16. Szleifer I. Protein adsorption on surfaces with grafted polymers: a theoretical approach. Biophys J 1997, 72:595-612.
17. 4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater 2007, 19:3163-3166.
18. Gombotz W.R., Wang G.H., Horbett T.A., Hoffman A.S. Protein adsorption to poly(ethylene oxide) surfaces. J Biomed Mater Res 1991, 25:1547-1562.
19. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf B 2000, 18:301-313.
20. Wang S.H., Dormidontova E.E. Nanoparticle design optimization for enhanced targeting: Monte Carlo simulations. Biomacromolecules 2010, 11:1785-1795.
21. Hong R.L., Huang C.J., Tseng Y.L., Pang V.F., Chen S.T., Liu J.J., et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficialα. Clin Cancer Res 1999, 5:3645-3652.
22. Parr M.J., Masin D., Cullis P.R., Bally M.B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 1997, 280:1319-1327.
23. Liu Y.T., Li K., Liu B., Feng S.S. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010, 31:9145-9155.
24. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
25. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
26. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31:7748-7757.
27. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010, 49:6288-6308.
28. Gao W.W., Langer R., Farokhzad O.C. Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed 2010, 49:6567-6571.
29. Feng S.S. Interpretation of mechanochemical properties of lipid monolayers at the air-water or oil-water interface and bilayer vesicles from equation of state or pressure-area measurement. Langmuir 1999, 15(4):998-1010.
30. Feng S.S. Reply to comment on interpretation of mechanochemical properties of lipid bilayer vesicles from the equation of state or pressure-area measurement of the monolayer at the air-water or oil water interface. Langmuir 2006, 22:2920-2922.
31. Feng S.S., Zhu G.H., Low M.Y. Effects of double bonds on the chains on the behaviour and compressibility of lipid monolayers at the air-water interface. Langmuir 2000, 16(19):7401-7410.